Therapy News and Research

RSS

£1.6 million grant awarded to advance development of MND drug candidate

Researchers from the University of Sheffield's Institute for Translational Neuroscience have been awarded a £1.6 million grant from the Medical Research Council.

26 Jan 2021

Prostate cancer: Drug-resistant, metastasis-causing cells can produce exponentially growing tumors

The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.

26 Jan 2021

Astrocytes might be a potential new target to better treat epilepsy

A significant number of epilepsy patients does not respond to currently available drugs. A collaboration between researchers in Japan and at the Heinrich Heine University Düsseldorf now addressed a cell type in the brain that has so far not received much attention in epilepsy therapy.

26 Jan 2021

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

Researchers have engineered an antibody that neutralizes SARS-CoV-2 with a potency that "rivals" current lead SARS-CoV-2 clinical neutralizing antibodies, and that also broadly neutralizes a range of clade 1 sarbecoviruses.

26 Jan 2021

Five-day regimen of radiotherapy safe, effective for men with high-risk forms of prostate cancer

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.

26 Jan 2021

Drug intervention may prevent heart damage caused by chemotherapy

There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.

26 Jan 2021

New partnership to develop test for predicting disease course in pediatric Crohn's patients

The Crohn's & Colitis Foundation, the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), has entered into a partnership with LifeArc, an independent medical research charity that advances translation of early science into health care treatments or diagnostics, to potentially develop the first clinical lab test to predict disease course in pediatric patients with Crohn's disease and response to treatment.

25 Jan 2021

Probiotics as adjuvant therapy for COVID-19 patients

In a recent review published in the Journal of Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Luigi Santacroce and Francesco Inchingolo et al. address the many factors such as dysbiosis (imbalance in the microbiota) that could influence the SARS-CoV-2 infection course.

25 Jan 2021

Study finds high prevalence of cardiovascular conditions in male breast cancer patients

Male breast cancer patients were found to have a high prevalence of cardiovascular conditions, in a small study of this rare patient population presented at the American College of Cardiology's Advancing the Cardiovascular Care of the Oncology Patient Virtual course.

25 Jan 2021

Stem cell based cell culture model to recapitulate important aspects of NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a widespread condition in the Western World. Around 30% of the population have lipid droplets stored in their liver which diminish its function in the long term.

25 Jan 2021

New method can help identify potential anti-cancer drugs at a high pace

The enzymes in human cells known as histone deacetylases, or HDACs, are targets for a handful of anticancer drugs because of their ability to affect gene expression.

25 Jan 2021

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

The cover for issue 2 of Oncotarget features Figure 4, "Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in "Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma" by Pérez-Lorenzo, et al. which reported that here, the authors showed that removing immune suppression and enhancing stimulatory signals increased the anti-tumor activity of unmodified TA99 antibodies with a significant reduction of growth of solid tumors and lung metastases in mouse models of melanoma.

25 Jan 2021

Reduced expression of TBX15 in tumor tissue represents a prognostic biomarker for HCC patients

The cover for issue 52 of Oncotarget features Figure 1, "Volcano plots of DNA methylation in tumor tissues compared with nontumor tissue," published in "Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma" by Morine, et al. which reported that the authors conducted a genome-wide analysis of DNA methylation of the tumor and non-tumor tissue of 15 patients with Hepatocellular carcinoma (HCC), and revealed TBX15 was the most hypermethylated gene of the tumor.

25 Jan 2021

Socioeconomic conditions linked to high viral load despite treatment for HIV patients in Ethiopia

For those who are diagnosed and have begun treatment for HIV, it is standard practice to regularly monitor viral load in the blood to assess response to treatment.

25 Jan 2021

Second-generation double antibody protects from SARS-CoV-2 and its tested variants

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants. It also prevents the virus from mutating to resist the therapy.

24 Jan 2021

New maintenance treatment for AML shows strong benefit for patients

Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites.

22 Jan 2021

Therapy News and Research

£1.6 million grant awarded to advance development of MND drug candidate

Prostate cancer: Drug-resistant, metastasis-causing cells can produce exponentially growing tumors

Astrocytes might be a potential new target to better treat epilepsy

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

Five-day regimen of radiotherapy safe, effective for men with high-risk forms of prostate cancer

Drug intervention may prevent heart damage caused by chemotherapy

New partnership to develop test for predicting disease course in pediatric Crohn's patients

Probiotics as adjuvant therapy for COVID-19 patients

Study finds high prevalence of cardiovascular conditions in male breast cancer patients

Stem cell based cell culture model to recapitulate important aspects of NAFLD

New method can help identify potential anti-cancer drugs at a high pace

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

Reduced expression of TBX15 in tumor tissue represents a prognostic biomarker for HCC patients

Socioeconomic conditions linked to high viral load despite treatment for HIV patients in Ethiopia

Second-generation double antibody protects from SARS-CoV-2 and its tested variants

New maintenance treatment for AML shows strong benefit for patients

Researchers identify protein that may represent a safer treatment target for pancreatic cancer

UC researchers test new combination therapy for head and neck cancer in animal models

NCCN provides new guidance for COVID-19 vaccinations in people with cancer

Combination therapy shows potential for treating lung cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News